Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PCDH7 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PCDH7 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PCDH7 Products |
| Gene Delivery | PCDH7 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PCDH7 Products |
| Benchmark Ab | Anti-PCDH7 Reference Antibody Recombinant positive control. |
View PCDH7 Products |
| Validator | PCDH7 siRNA Set For knockdown verification. |
View PCDH7 Products |
| Related Target A | EGFR EGFR is a key target in lung cancer; parallel biomarker for NSCLC. |
View EGFR Products |
| Related Target B | KRAS Parallel oncogenic driver mutated in solid tumors. |
View KRAS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Extracellular Domain Conformation | HEK293 Expressed (Native Glycosylation), preserving correct folding. |
| Cross-reactivity & Homolog Screening | Sequence Verified human and cyno orthologs available with >95% purity. |
| Lack of Reliable Controls | Recombinant Benchmark Antibodies included for standardizing assays. |
| False Positives in Cell Assays | Sequence-verified siRNA included for rigorous specificity validation. |
Live PCDH7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The exploration of PCDH7 (Protocadherin-7) as a therapeutic target is gaining traction, particularly in solid tumors such as non-small cell lung cancer (NSCLC) and gastric cancer. As an adhesion molecule often overexpressed in malignant tissues, it presents a compelling case for targeted therapies. The next wave of R&D is focusing on exploiting its high surface expression for antibody-drug conjugates (ADCs) and investigating its expression profile alongside other established lung cancer drivers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC / mAbs | Preclinical Biotech | NSCLC, Gastric Cancer | Internalization Assay (Need high-purity ECD-Fc) |
| CAR-T / Cell Therapy | Academic / Early Pharma | Solid Tumors | Binding & Specificity (Need Native Glycosylated Antigens) |
| Combination Strategies | Translational Labs | Refractory Cancers | Parallel Screening (Need parallel target proteins like EGFR/KRAS) |